Merck & Co., Inc. (NYSE:MRK) Expected to Post Quarterly Sales of $12.43 Billion

Brokerages expect that Merck & Co., Inc. (NYSE:MRK) will post $12.43 billion in sales for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Merck & Co., Inc.’s earnings, with estimates ranging from $12.20 billion to $12.77 billion. Merck & Co., Inc. reported sales of $12.55 billion in the same quarter last year, which would suggest a negative year-over-year growth rate of 1%. The company is expected to announce its next earnings report before the market opens on Thursday, October 28th.

According to Zacks, analysts expect that Merck & Co., Inc. will report full-year sales of $47.03 billion for the current financial year, with estimates ranging from $46.08 billion to $47.96 billion. For the next year, analysts forecast that the company will post sales of $50.04 billion, with estimates ranging from $48.17 billion to $52.00 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that cover Merck & Co., Inc..

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Wednesday, July 28th. The company reported $1.31 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.31. Merck & Co., Inc. had a return on equity of 50.93% and a net margin of 11.48%. The business had revenue of $11.40 billion during the quarter, compared to analysts’ expectations of $11.21 billion. During the same period in the previous year, the company posted $1.37 earnings per share.

MRK has been the subject of several recent analyst reports. Morgan Stanley cut Merck & Co., Inc. from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $90.00 to $85.00 in a research note on Tuesday, September 7th. SVB Leerink upped their price target on shares of Merck & Co., Inc. from $99.00 to $101.00 and gave the stock an “outperform” rating in a report on Friday, July 30th. Truist began coverage on Merck & Co., Inc. in a report on Tuesday, July 27th. They issued a “buy” rating and a $92.00 price objective for the company. Truist Securities began coverage on Merck & Co., Inc. in a report on Tuesday, July 27th. They issued a “buy” rating and a $76.79 price objective for the company. Finally, JPMorgan Chase & Co. decreased their price objective on Merck & Co., Inc. from $105.00 to $100.00 and set an “overweight” rating for the company in a report on Wednesday, June 9th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $91.09.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. State Street Corp lifted its position in shares of Merck & Co., Inc. by 1.2% during the 2nd quarter. State Street Corp now owns 114,073,945 shares of the company’s stock worth $8,943,537,000 after buying an additional 1,385,011 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Merck & Co., Inc. by 3.4% during the 2nd quarter. Geode Capital Management LLC now owns 44,209,748 shares of the company’s stock worth $3,429,289,000 after buying an additional 1,435,230 shares in the last quarter. Franklin Resources Inc. lifted its position in shares of Merck & Co., Inc. by 9.4% during the 2nd quarter. Franklin Resources Inc. now owns 38,804,709 shares of the company’s stock worth $3,017,843,000 after buying an additional 3,348,929 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Merck & Co., Inc. by 15.8% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 26,293,818 shares of the company’s stock worth $2,044,871,000 after buying an additional 3,594,415 shares in the last quarter. Finally, Morgan Stanley lifted its position in shares of Merck & Co., Inc. by 17.1% during the 2nd quarter. Morgan Stanley now owns 26,289,496 shares of the company’s stock worth $2,044,534,000 after buying an additional 3,832,086 shares in the last quarter. 71.83% of the stock is currently owned by institutional investors and hedge funds.

NYSE MRK opened at $71.93 on Tuesday. The business has a fifty day moving average price of $76.21 and a two-hundred day moving average price of $76.57. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.31 and a quick ratio of 1.06. Merck & Co., Inc. has a fifty-two week low of $70.89 and a fifty-two week high of $85.60. The stock has a market capitalization of $182.08 billion, a PE ratio of 32.84, a PEG ratio of 2.16 and a beta of 0.41.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 7th. Investors of record on Wednesday, September 15th will be given a $0.65 dividend. The ex-dividend date of this dividend is Tuesday, September 14th. This represents a $2.60 annualized dividend and a yield of 3.61%. Merck & Co., Inc.’s payout ratio is 43.77%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Featured Article: Net Asset Value

Get a free copy of the Zacks research report on Merck & Co., Inc. (MRK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.